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Background: Generic Medicines are an important policy option allowing for access to affordable, essential
medicines. Quality of generic medicines must be guaranteed through the activities of national medicines regulatory
authorities. Existing negative perceptions surrounding the quality of generic medicines must be addressed to
ensure that people use them with confidence. Campaigns to increase the uptake of generic medicines by
consumers and providers of healthcare need to be informed by local norms and practices. This study sought to
compare South African consumers’ and healthcare providers’ perceptions of quality of generics to the actual quality
of selected products.
Methods: The study was conducted at the local level in three cities of South Africa: Johannesburg, Durban and
Cape Town. Purposive sampling was used to recruit consumer participants (n = 73) and random sampling used to
recruit healthcare providers from public and private sectors (n = 15). Data were obtained through twelve focus
group discussions with consumers and semi-structured interviews (n = 15) with healthcare providers in order to
gain familiarity with perceptions of quality. One hundred and thirty five products comprising paracetamol tablets
(n = 47), amoxicillin capsules (n = 45) and hydrochlorothiazide tablets (n = 43) were sourced from public and private
sector healthcare providers. These products were subjected to in vitro dissolution, uniformity of weight and identity
(Fourier Transformed Infrared Spectroscopy) tests using prescribed methods from the British (2005) and United
States Pharmacopeias (2006).
Results: Respondents described drug quality in relation to the effect on symptoms. Procurement and use behavior
of healthcare providers was influenced by prior experience, manufacturers’ names and consumers’ ability to pay. All
formulations passed the in vitro tests for quality.
Conclusions: This study showed clear differences between perceptions of quality and actual quality of medicines
suggesting deficiencies in public engagement by government regarding the implementation of generic medicines
policy. Implementation of generic medicines policy requires the involvement of consumers and healthcare
providers to specifically address their information gaps and needs.Background
Generic medicines policies are used by governments to
improve access to affordable medicines. Successful up-
take of this policy is dependent on society having confi-
dence in the efficacy, safety and quality of generic
medicines [1,2]. Together with medicines promotion, we
know that commercial features of medicines like price
and brand names affect peoples’ perceptions of efficacy* Correspondence: aarti@sarpam.net
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reproduction in any medium, provided the orand safety [3]. Additionally, there is a prevailing notion
that generic medicines are inferior in quality [2]. These
perceptions are further reinforced by recent studies that
found increasing numbers of poor quality medicines in
the developing world [4,5]. Whilst the issue of poor
quality medicines has to be urgently addressed, negative
perceptions about generic medicines must be managed
through proper engagement of all stakeholders in those
settings where the regulatory environment delivers
quality-assured medicines [2,6,7].
A medicine is considered to be poor quality when
it does not meet established standards in terms of
identity, purity, bioavailability of the active pharmaceuticald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the finished product [8]. This description frames
quality within a technical paradigm. Studies assessing
quality tend to focus on measuring drug content; lim-
ited research is undertaken on how the concept of
quality is understood by the general public and
healthcare providers [9]. Consumers have been shown
to rely on the advice of their healthcare providers
[10,11], with providers relying on experience, pharma-
ceutical marketing, prior use and clinical outcomes
when making decisions about which medicines to use
[3,10]. Increasingly, we recognize that the use of med-
icines is influenced by shared experiences and knowledge
informed by local contexts [12,13].
South Africa introduced the National Medicines Policy
in 1996. Whilst generic medicines have always been part
of the system, the focus has mainly been in the public
sector. From mid 2000, when medicine prices become a
critical issue, generic medicines have been recommended
for wider use, including the private sector. The objec-
tives of this study were to explore consumers’ and provi-
ders’ perceptions of quality of medicines, assess the
quality of selected essential medicines and ultimately
compare the perceptions of quality to the actual quality
of the products tested. The findings, showing a discon-
nect between perceptions of quality to the actual quality,
indicate that implementation of the generic medicines
policy in South Africa requires a multi-pronged ap-
proach that is developed through the participatory
mechanisms that pay attention to the social, economicTable 1 Description of consumer participants










Cape Town 10 6
11 6
12 5
Informal Employment: domestic worker, driver, cleaner, security.
Formal Employment: police, teacher, lawyer, admin officer.and cultural contexts of the intended beneficiaries, i.e.
the users and the providers.
Methods
The study was conducted in three South African cities,
Durban, Johannesburg and Cape Town, from 2006 to
2008. Qualitative methods, consisting of focus group dis-
cussions with seventy-three consumers, and interviews
with fifteen healthcare providers, were used to gain famil-
iarity with users’ and providers’ views on quality of medi-
cines as well as generic medicines. Participants were
recruited through purposive sampling. Twelve focus
groups - four in Johannesburg, five in Durban and three in
Cape Town - were conducted with consumers from differ-
ent ethnicities, ages, gender and socio-economic status.
Recruitment of consumer participants followed a two
stage process. Initially eleven key informants were identi-
fied from existing networks developed by the first author
through her prior work in South Africa. These key infor-
mants then recruited the remaining consumer participants
through snowball sampling. Table 1 describes the charac-
teristics of the consumer participants.
Fifteen semi-structured interviews were conducted
with healthcare providers from both the private and
public health sectors in South Africa. Private sector pro-
viders were randomly selected within a particular geo-
graphic location. This involved drawing up a list of
medical practices and community pharmacies in the
suburb where the first author stayed during the data col-
lection period. The list was informed by local residentsGender Age Employment (formal/informal)
Female 20 – 60 informal
Male 20 – 48 informal
Male (3) 28 – 63 formal
Female (3)
Male (5) 25 – 56 Formal
Female (2)
Male 28 – 48 Informal
Male (4) 27 – 54 Formal
Female (2)
Female 37 – 64 Formal
Male 68 – 87 Retired
Male 16 – 19 Students
Female 25 – 53 Informal
Male (3) 27 – 38 Formal
Female (3)
Female 65 – 73 Retired
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introducing the study were drafted and delivered by local
contacts to a total of twelve practices that consisted of
six medical practices and six pharmacies. The idea was
to approach a minimum of two medical practices and
two pharmacies, per suburb, to interview the doctors,
nurses and pharmacists. Letters introducing the project
were sent out and permission sought to interview the re-
spective providers. Three pharmacy and three medical
practices granted us permission for interviews. Two of
the medical practices were dispensing doctor practices.
The three pharmacies consisted of one chain store phar-
macy and two independent pharmacies. Through this
process eight private practitioners were recruited: three
general practitioners, two nurses and three pharmacists.
For the public sector, provincial staff, known to the first
author from her previous work in South Africa, were
approached and asked to participate. Two pharmacists,
three doctors and two nurses were included from the
public sector. Table 2 describes the characteristics of
these providers.
The aim of the focus group discussions with consu-
mers and interviews with providers was to gather
insights into peoples’ understanding of quality and use
of generic medicines rather than reaching consensus on
quality of generic medicines. Therefore, due to time and
cost limitations, the above approaches to recruitment of
participants were adopted.
The following issues for both the consumers and
healthcare providers were explored during the group dis-
cussions and interviews:
– Describe your understanding of the quality of a
medicine?
– Where do you get your medicines from? Why do
you use this source?
– Which product would you use to treat a headache
(shown two versions of paracetamol: PanadoR
(original) and PacimolR (generic)?Table 2 Description of healthcare providers
City Provider Public Private
Johannesburg Doctor 1 1
Nurse 1 1
Pharmacist 1 2
Durban Doctor 1 -
Nurse 1 -
Pharmacist 1 1
Cape Town Doctor 1 2
Nurse - -
Pharmacist - 1– Which product would you use to treat an infection
(shown two versions of amoxicillin: AmoxilR
(original) and MoxypenR (generic)?
All focus group discussions and interviews were tape-
recorded, transcribed by an assistant and coded with the
aid of NVivo, version seven. Initial coding was predom-
inantly open and performed by the first author. During
coding three distinct themes were emerging: quality was
understood in relation to effects on clinical symptoms,
acceptability and use of generic medicines was based on
product names, prices paid or source of supplier. After
coding according to these themes, the data were then
reviewed individually by the others. The analysis was
shared with the participants (e-mailed back to the
healthcare providers and summarized with focus group
participants at the conclusion of group discussions).
Their feedback was incorporated into the final analysis.
In vitro analysis was performed on 135 samples of
selected products that consisted of paracetamol tablets,
hydrochlorothiazide tablets and amoxicillin capsules.
These three medicines are on the national essential med-
icines list and are used to treat pain (paracetamol),
hypertension (hydrochlorothiazide) and infection (amoxi-
cillin) at primary care level in South Africa [14]. They are
available in both the private and public sectors as tablets,
capsules and suspensions. The patents on all these medi-
cines have expired and many branded generic versions
are available in the country. The originator brand of
paracetamol in South Africa is PanadoR. For amoxicil-
lin, this is AmoxilR . Both amoxicillin and hydrochlor-
othiazide, classified as prescription medicines, require
a medical prescription when being purchased in South
Africa. Paracetamol can be bought over the counter with-
out a prescription.
For this study we obtained our sample of products
from sources commonly used by the consumers. Consu-
mers identified three main sources for medicines: the
public sector (clinic or hospital), dispensing doctors, and
community pharmacies. For the public sector medicines
from eleven clinics and hospitals in Durban, KwaZulu-
Natal were procured after permission was granted by the
provincial Department of Health. Dispensing doctors in
Durban and Johannesburg were approached, told about
the study, and asked to provide medicines. Medicines
were supplied by seven doctors, four in Durban and
three in Johannesburg. Medicines were purchased for
cash, using prescriptions written by a South African
medical colleague, from thirty community pharmacies:
eleven in Durban, ten in Johannesburg and nine in Cape
Town. Here the data collector started at a central point
in the respective city and went to pharmacies within a
20 kilometer radius until approximately ten sites were
visited in a single day to purchase the medicines.
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brand decided by the supplier.
Twenty-nine generic medicines were sourced from the
public sector. The remaining 106 samples were sourced
from the private sector (dispensing doctors and commu-
nity pharmacists). Of these, six were samples of PanadoR
and four were samples of AmoxilR, representing innov-
ator brands. Therefore, out of the total of 135 samples,
ten were innovator brands supplied solely by the private
sector and the remaining 125 samples were branded and
unbranded generics from both the public and private
sectors. Table 3 provides a description of the medicines
assessed in this study.
Several tests can be performed on a medicine to deter-
mine its quality; tests for identity, content, disintegration,
dissolution, stability, sterility, impurity, bioavailability and
bioequivalence as per the monographs in the relevant
pharmacopeias. This study focused on assessing theTable 3 Description of medicines tested
Drug Brands/Name on label Public
(no. o
























Amoxicillin 500 mg capsule Amoxicillin -
Moxypen 3
Maxcil -identity, dissolution and uniformity of weight. Identity
testing is crucial because this verifies the active pharma-
ceutical ingredient. Fourier transformed infrared spectros-
copy (FTIR) was used to assess the identity of the
products according to the monographs of the 2005 British
Pharmacopeia (BP) for amoxicillin rehydrate 250 mg and
500 mg capsules, hydrochlorothiazide 25 mg tablets, and
paracetamol 500 mg tablets. Amoxicillin (Sigma-Aldrich
Chemie GmbH; Steinheim, Germany, Lot.112 K0481),
Hydrochlorothiazide (Sigma-Aldrich Chemie GmbH;
Steinheim, Germany; Lot 115 K1112) and Paracetamol
(4-Acetamidophenol) 9Sigma-Aldrich Chemie GmbH;
Steinheim, Germany; Lot 11 K0253) were the drug stan-
dards used in the tests.
Dissolution tests were performed to determine the rate
and amount of active drug going into solution in a speci-
fied medium, following the specifications of the drug
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hydrochlorothiazide 25 mg tablets and amoxicillin 500 mg
capsules; Apparatus I (basket apparatus) was used for the
amoxicillin 250 mg capsules. The amount of drug going
into solution at the respective times was measured using
ultraviolet spectrophotometer and compared to the speci-
fications of the BP, 2005.
Uniformity of weight of the formulation was also
assessed as a proxy measure of quality control during the
manufacture, packaging and distribution of the product.
The tablets and capsules were analyzed according to the
percentage deviation as recommended in the BP, 2005.
Ethical approval for this study was granted by the




For consumers, the main descriptor of quality was the
effect of the medicine on their symptoms. Terms used to
describe quality included “drug works” and “strong
medicine”. The following statements capture the general
theme of associating the quality of a medicine with the
effect it produces on symptoms:
“Quality is like a standard: low, medium, high. Low
standard medicines equal something that doesn’t
work. Is about the way it works, side-effects of it, effects
of it” (Johannesburg, group 1).
“The only way I can define quality is if I drink it and
see it works” (Cape Town, elderly).
Similar to the consumers, healthcare providers also
described quality of medicines in relation to alleviation of
symptoms felt by their patients or side-effects produced.
“Quality essentially has to do with how effective and
how safe your product is for a patient” (Pharmacist -
private).
“Quality would first mean efficacy. Secondly it must
have minimal side-effects. Lastly it must be
consumable” (Doctor – private).
Use of generic medicines
The majority of our consumers did not seem to be
knowledgeable about generic medicines. In terms of self-
treatment with over the counter medicines for minor ail-
ments, such as a headache, consumers tended to identify
with PanadoR, the innovator brand, rather than Paci-
molR, a branded generic. PanadoR was a familiar brand,
it was well advertised, and people had used this before
where they had experienced relief of their symptoms.On the other hand, few respondents had seen PacimolR,
the branded generic.
“Panado is popular, used this before. It is the first time
I am seeing this (Pacimol)” (Johannesburg, group 2).
“It (Panado) has been recommended by a lot of people,
see it advertised” (Durban, group 1).
In terms of acceptability of generics regarding prescrip-
tion medicines, consumers generally tended to rely on the
advice of their prescriber, rather than the dispenser.
“I think if a doctor is prescribing it and he says the
generic will be equally potent then I will use it. If I
took a script for something and the pharmacist
suggested a generic and the doctor had not told me I
could use it, then I would be hesitant” (Cape Town,
group 1),
At the same time, generics were acceptable to those
consumers who had chronic illnesses and where cost
played a deciding role in medicines use.
“We actually go looking for generics because it is
cheaper and we are huge consumers of medicines”
(Durban, group 2).
The healthcare providers all felt that the quality of
medicines in South Africa was good. They reported that
their selection of generic products was based on prior
experiences with a particular product in terms of its effi-
cacy. The message was a clear one of choosing medi-
cines that were tried and tested either by them or their
colleagues:
“You’re seeing 15 – 20 patients a day and you’re using
the drugs for that certain period over the 5 or 10 or
15 years and it works. So essentially it’s the
effectiveness of the drug that I base my stuff on”
(Doctor – private).
The dispensing doctors mentioned two key factors influ-
encing their use of generic medicines: cost to the patient;
and name of the company supplying the medicines:
“It also depends on the patient profile where you’ve got
an elite patient that will ask for the Panado (a brand
name drug) whereas a B or C category patient I would
use a generic, like amoxicillin” (Doctor - private).
“I am happy to use generics if it’s from a reputable
company. There are some companies in SA where you
don’t actually know what or how safe that drug is and
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you use it” (Doctor - private).
Apart from the reputation of the company, which
appears to have been assessed through experience with
their products, some providers had negative perceptions
about products supplied by companies from India and
China:
“If you say to me something’s coming from China, you
think about China as being inferior quality in general,
with everything else and you wonder from a medical
point of view do you actually trust this type of
medical, and pharmaceutical industry and
developments?” (Nurse - private).
“I went to the launch of a product by Dr Reddys. It
was incredibly well done. But the problem is I think
with the name. If it comes from the East you tend to
trust it less. If it comes from Germany, Switzerland you
tend to trust it more. So basically where I think they
need to either dispel those myths through education”
(Pharmacist - private).
Similarly, consumers felt that generic medicines were
inferior and referred to these as being “fong kong”, a
term used to describe fake goods in Johannesburg.
Managerial interventions were also instrumental in
promoting the use of generic medicines. Public sector
prescribers were restricted to using what was on their
institution’s medicines list. Prescriptions were also writ-
ten using non-proprietary names.
“I always use generics for prescribing. Our department
doesn't allow prescribing using trade names. We use
what is available from PMSC (Medicines’ depot). The
tender changes intermittently so we stick to generics to
avoid confusion” (Doctor - public)
Below is the description by one of the private sector
respondents regarding how financial incentives were
used to ensure pharmacists within their chain of phar-
macies dispensed specific generics:
“What’s happened now at head office is they have
preferred products. Probably because of kickbacks, we
don’t have that much information. But on the system
you’ll get AugmentinR, if you choose AugmentinR for
an example, and then they will say the first preferred
product, the second preferred product, the third
preferred product etc. . . What they’ve now started
doing is, if you dispense ‘x’ amount of their preferred
products, you get a kickback – the pharmacist, each
pharmacist, if you get within a certain percentage. Itamounts to about R1000 (~$137) a month”
(Pharmacist - private).
Quality concerns
Concerns about the actual quality of medicines were expli-
citly raised by the public sector pharmacists interviewed.
These two pharmacists worked from the provincial medi-
cines’ depots where medicines were received from the
suppliers and then distributed to health facilities. They
dealt directly with product quality. They reported con-
cerns that medicines intended for use at primary care fa-
cilities were not monitored as effectively as more
expensive drugs. One said that complaints regarding qual-
ity concerns were not adequately dealt with either by the
provincial procurement agency or the Medicines Control
Council. This created frustration since staff at health care
facilities were asked to report drug quality problems but
when there was limited feedback, or worse when the
supplier was awarded the tender again, it was difficult
to remain motivated:
“Despite numerous reports these companies still get the
tender. The sad part is the hospital pharmacists,
nursing personnel and patients question the tenders
being awarded to such suppliers! My response is “It’s
not in my hands” (Pharmacist - public).
Consumers also acknowledged their limitations in ac-
tually assessing quality of medicines and tended to use
the price they paid as a key measure of quality. Cheaper
medicines were considered to be inferior and people
viewed these with a degree of suspicion.
“Can I ask something from a layman’s point of view?
Why are generics cheaper than originals? They make
generics for the people who cannot afford the expensive
ones or they are just making quick money?”
(Johannesburg, group 2).
“No, I am thinking in my mind, why this one
(Pacimol) is R2 (0.30 cents) but is the same as
Panado? If I do not have money, I will buy it but. . .
(shakes her head)” (Johannesburg, group 1)
In vitro analysis of medicines
Out of the 135 preparations tested all samples passed the
test for identity. Twelve samples did not pass the phase
one of the dissolution testing. There were insufficient
tablets within these samples to proceed to phase two dis-
solution testing. Therefore, results for dissolution testing
were positive and conclusive for 123 samples. One hun-
dred and thirty two samples passed the uniformity of
weight tests. Physical inspection of these samples showed
breakages that probably occurred during the transport of
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results were positive for all samples tested. Therefore, there
do not appear to be any differences between products
sourced from the private or public providers or between
innovator brands, branded generics or unbranded generics.
Discussion
The findings of this study must be considered within its
limitations. These were the small sample size of both the
products tested and the number of interview and focus
group participants. Purposive sampling of the consumer
participants and reliance on local knowledge for the
drafting of the list of medical and pharmacy practices,
has probably biased the study respondents towards the
urban and peri-urban settings of South Africa. Time and
financial constraints forced us to be pragmatic and adopt
our sampling approaches. The study findings, however,
highlight issues that were common to all participants that
may well be indicative of the perceptions of the wider
population. In this sense, further research informed by the
findings of this study with a larger group of respondents
would be useful. The findings also suggest limitations in
the implementation of the generic medicines policy by
both government and generic manufacturers as far as pro-
viders and consumers are concerned, including lack of in-
formation for consumers and an apparent lack of
sensitivity in dealing with quality complaints from health-
care providers. Additional detail on South African con-
sumer perceptions of quality of medicines is presented by
the authors in another publication [11].
Our findings regarding the in vitro tests provide evi-
dence that the products assessed from South Africa
meet the quality standards as established in the British
and United States Pharmacopeia. The two innovator
medicines assessed in this study, PanadoR and AmoxilR,
were both supplied by private sector providers. All sam-
ples from the state sector were branded or unbranded
generic products. We found no major differences in the
quality of products provided by the state sector when
compared to those supplied by the private sector, or be-
tween innovator and generic brands. These in vitro find-
ings are much more positive when compared to other,
similar studies undertaken in Africa [15,16].
The findings regarding peoples’ perceptions demon-
strate a marked consistency between consumers and
healthcare providers in their description of quality of
medicines: their concerns are about the safety and effi-
cacy of the medicine on relief of symptoms. From this
perspective all respondents generally agreed that the
quality of medicines in South Africa was good. We
found a clear difference between what consumers per-
ceive as being inferior medicines and the actual quality
of medicines. Similarly, whilst most healthcare provi-
ders were more positive about the quality of genericmedicines, there were certain reservations about quality
expressed by pharmacists working in the state sector.
These reservations were informed in a large part by the
lack of feedback provided to these pharmacists after
product quality complaints were made.
Additional reservations against generic medicines by
healthcare providers appeared to be driven by internally
held beliefs about products that were manufactured
in eastern countries such as India and China. These
respondents felt that, in general, products from these
countries were inferior and transferred this perception
to medicines produced there as well. The link to the East
was also evident when consumers from Johannesburg
referred to perceived fake medicines as “fong kong”.
However, Schumaker and Bond’s research in Zambia
suggests that such attitudes about products from the
East are beginning to change [17]. They found increasing
acceptance, by healthcare providers, of generic antiretro-
viral medicines from India because these were shown to
improve health outcomes and were readily available [17].
Suspicion was directed at generic medicines as demon-
strated by the majority of participants selecting PanadoR,
the original brand, over PacimolR, a generic. PanadoR was
familiar and its effects were known to them; PacimolR was
the unknown. The need to engage the public through the
provision of trustworthy information about generic medi-
cines should allow for greater acceptance [2].
Understanding the disconnect between providers’ and
consumers’ perceptions of quality in comparison to the
actual quality probably lies in the subject domains within
which medicines and their actions are interpreted. Medi-
cines are chemical entities that have been developed into
dosage forms allowing people to consume them and gain
the benefits of the active drug [18]. When people con-
sume medicines they experience the effects of them. The
dominant paradigm governing this experience is the
pharmacological one [19]. Therefore, when measuring
the quality of medicines the focus is on the biochemical
properties of the drug. The pharmacological paradigm
fails to explain other aspects that form part of the medi-
cine use experience, especially differences in the descrip-
tion of effects by the patient compared to those of the
clinician or even the placebo effect [20,21]. More specif-
ically, the pharmacological approach fails to explain why
some consumers and healthcare providers felt that the
cheaper, generic medicines were inferior because these
took too long to work. Understanding the experiences and
perspectives of those who consume medicines requires
policymakers, implementing agencies and researchers to
address some of the inadequacies of the purely biomedical
perspective and to explore more fully the socio-cultural
framework within which medicines use occurs [1,13].
South Africa has legislation and regulations to support
the use of generic medicines. This study shows that the
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communicated to consumers and healthcare providers.
The South African government, through the National
Medicines Policy and the Essential Medicines Pro-
grammed has recommended that tertiary institutions
introduce concepts like generic medicines, essential
drugs and standard treatment guidelines into under-
graduate medical, nursing and pharmacy curricula [22].
These concepts must be embraced by all: students, aca-
demics, professional councils and associations to ensure
there is a common understanding and for common mes-
sages to be shared with the public regarding quality and
safety of generic medicines. Also, recent reports about
the challenges faced by South Africa’s Medicines Regula-
tory Authority further fuel negative perceptions around
quality of generic medicines and needs to be addressed
[23]. Finally, the potential for savings from the use of
generic medicines is widely recognized by policymakers
so communicating this to the South African public
remains an important issue [24].
Conclusion
The implication from our study is that there needs to be a
wider acceptance by governments that medicines do have
a “social origin”, and consumers’ and providers’ percep-
tions must explicitly be addressed if the ultimate goal of
improving access to quality assured, affordable medicines
is to be realized. In Africa, where access to medicines
remains critical, it is timely to start understanding and
addressing the problems within the social paradigm
[1,10,11] as well as building trust in the agencies respon-
sible for regulation quality and safety of medicines.
Competing interests
The authors have no competing interests to declare.
Authors’ contributions
The study was designed by all four authors. Field work, laboratory testing
and initial analysis was undertaken by AP. RG and PN reviewed the
qualitative findings. TR reviewed the in-vitro results. The paper was initially
drafted by AP, with review and additions by the others. All authors read and
approved the final manuscript.
Author details
1Southern African Development Community (SADC), PO Box 95, Gaborone,
Botswana. 2Hera: right to health & development, Reet, Belgium. 3Department
of Preventive and Social Medicine, University of Otago Medical School, PO
Box 913, Dunedin 9054, New Zealand. 4New Zealand's National School of
Pharmacy, University of Otago, PO Box 56, Dunedin 9054, New Zealand.
Received: 28 February 2012 Accepted: 21 August 2012
Published: 3 September 2012
References
1. Pound P, Britten N, Morgan M, et al: Resisting medicines: a synthesis of
qualitative studies of medicine taking. Social Science and Medicine 2005,
61(1):133–155.
2. King D, Kanavos P: Encouraging the use of generic medicines:
Implications for Transition Economies. Croatian Medical Journal 2002,
43(4):462–469.3. Waber R, Shiv B, Carmon Z, Ariely D: Commercial features of placebo and
therapeutic efficacy. JAMA 2008, 299(9):1016–1017.
4. Caudron J, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J:
Substandard medicines in resource-poor settings: a problem that can no
longer be ignored. Tropical Medicine and International Health 2008, 13
(8):1062–1072.
5. Cockburn R, Newton P, Agyarko E, Akunyili D, White N: The global threat of
counterfeit drugs: why industry and governments must communicate
the dangers. PLoS Med 2005, 2(4):e100. doi:10.1371/journal.pmed.0020100.
6. Mansfield PR, Mintzes B, Richards D, Toop L: Direct to consumer
advertising. British Medical Journal 2005, 330(7481):5–6.
7. Freudenberg N, Galea S: The impact of corporate practices on Health:
Implications for Health Policy. Journal of Public Health Policy 2008,
29(1):86–104.
8. Quick J, Rankin J, O'Connor, et al (Eds): Managing drug supply: the selection,
procurement, distribution and use of pharmaceuticals, 2nd edition, revised and
expanded. Connecticut: Kumarian Press; 1997.
9. Newton P, Lee S, Goodman C, et al: Guidelines for field surveys of the
quality of medicines: A proposal. PLoS Medicine 2009, 6(3):e1000052.
10. Syhakhang L, Freudenthal S, Tomson G, Wahlström R: Knowledge and
perceptions of drug quality among drug sellers consumers in Lao PDR.
Health Policy and Planning 2004, 19(6):391–401.
11. Patel A, Gauld R, Norris P, Rades T: "This body does not want free
medicines": South African consumer perceptions of drug quality. Health
Policy and Planning 2010, 25(1):61–69.
12. Radyowijati A, Haak H: Improving antibiotic use in low-income countries:
an overview of evidence on determinants. Social Science and Medicine
2003, 57(4):733–744.
13. Williams H, Jones C: A critical review of behavioural issues related to
malaria control in sub-Saharan Africa: what contributions have social
scientists made? Social Science and Medicine 2004, 59(3):501–523.
14. Department of Health: Standard treatment guidelines and Essential Drugs List.
editionth edition. South Africa: Pretoria: DoH; 2003.
15. Taylor R, Shakoor O, Behrens R, et al: Pharmacopoeial quality of drugs
supplied by Nigerian pharmacies. Lancet 2001, 357(9272):1933–1936.
16. Bate R, Coticelli P, Tren R, Attaran A: Antimalarial drug quality in the most
severly malariaous parts of Africa - A six country study. PLoS One 2008, 3
(5):e2132. doi:10.1371/journal.pone.0002132.
17. Schumaker LL, Bond VA: Antiretroviral therapy in Zambia: Colours,
"spoiling", "talk" and the meaning of antiretrovirals. Social Science and
Medicine 2008, 67(1):2126–2134.
18. Kroeger A: Anthropological and socio-medical health care research in
developing countries. Social Science and Medicine 1983, 17(3):147–161.
19. Montagne M: The Pharmakon Phenomenon: Cultural conceptions of
drugs and drug use. In Contested Ground: public purpose and private interest
in the regulation of prescription drugs. Edited by Davis P. New York: Oxford
University Press; 1996:11–25.
20. Whyte SR, van Der Geest S, Hardon A (Eds): Social lives of medicines.
Cambridge: Cambridge University Press; 2002.
21. Kleinman A, Eisenberg L, Good B: Culture, Illness, and Care: Clinical
lessons from anthropologic and cross-cultural research. The Journal of
Lifelong Learning in Psychiatry 2006, iv:140–149.
22. Zuma N: South Africa's new national drug policy. Journal of Public Health
Policy 1997, 18(4):98–105.
23. Health24 (2010): The MCC Mess; 2010. http://www.health24.com/printarticle.
htm, accessed 31 May 2010.
24. WHO: The world health report: Health Systems Financing: the path to universal
coverage. Geneva: WHO Press; 2010.
doi:10.1186/1472-6963-12-297
Cite this article as: Patel et al.: Quality of generic medicines in South
Africa: Perceptions versus Reality – A qualitative study. BMC Health
Services Research 2012 12:297.
